trending Market Intelligence /marketintelligence/en/news-insights/trending/66PZkES4JuPPFnCihxfQpg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Apellis Pharmaceuticals prices $351.5M common stock offering

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Apellis Pharmaceuticals prices $351.5M common stock offering

Apellis Pharmaceuticals Inc. priced its offering of 9.5 million common shares at $37 per share.

The Waltham, Mass.-based biopharmaceutical company also granted underwriters a 30-day option to buy up to an additional 1,425,000 common shares at the same price.

Gross proceeds are expected to be about $351.5 million.

Citigroup, J.P. Morgan and Evercore ISI are acting as joint book-running managers for the offering, while Cantor Fitzgerald & Co. and Baird are acting as lead managers.

Apellis develops therapies through the inhibition of the complement system for autoimmune and inflammatory diseases. In Jan. 7, the company said a late-stage study showed that its drug APL-2 increased hemoglobin protein in patients with paroxysmal nocturnal hemoglobinuria — a rare life-threatening disease that destroys red blood cells during a late-stage study.